A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Of Atezolizumab (Anti-PD-L1 Antibody) As Adjuvant Therapy In Patients With Renal Cell Carcinoma At High Risk Of Developing Metastasis Following Nephrectomy

UCI-16-84
NCT03024996
Cancer - Kidney
Edward Uchio
Open
Treatment
III
Adult
Local

For information about cancer clinical trials at the UCI Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.